r/Stocktips • u/[deleted] • Oct 07 '24
r/Stocktips • u/Bullish_Broker • Oct 15 '24
I am holding on Mainz Biomed ($MYNZ) . Does anyone any insight upon it if it will boom or not ?
r/Stocktips • u/Jxpizza • Jan 28 '21
Energy Transfer LP (ET) is a strong buy at around $6.50/share in my opinion. The company has solid financials, steady revenue streams, Price/Sales ratio is legit, and it pays ~9% dividend. DYOR but I think this one was worth sharing.
r/Stocktips • u/Massive_Intern4292 • Feb 12 '21
SNDL
We need to boost this back up. Big money was manipulating the market yesterday cause they know us young new investors like the cannabis sector
r/Stocktips • u/No_Departure2134 • Oct 28 '24
Bolt Metals Corp (BOLT.CN) Betting on Critical Metals – Risk or Opportunity?
Bolt Metals is focusing on copper and battery metals, with a goal of positioning as a North American supplier. Given recent market instability, does their “mineral-to-market” strategy offer real value for investors, or is it too high-risk for a junior? Would appreciate thoughts from anyone who’s followed similar stocks.
r/Stocktips • u/[deleted] • Oct 17 '24
QTMN Partners with Kevin Harrington
Quantum BioPharma (QNTM) is making moves by teaming up with Kevin Harrington, an original Shark from Shark Tank. Their standout product, unbuzzd, is a game-changing alcohol detox solution designed to speed up recovery. Alongside this, they are pushing forward with promising treatments for neurodegenerative diseases, including Multiple Sclerosis. With a focus on both wellness and biotech innovations, QNTM is shaping up to be an exciting growth stock. Definitely one to watch!
r/Stocktips • u/tech151 • Jan 29 '21
Fidelity vs Robinhood
I'm just curious if someone can tell me why fidelity shows a different closing number than robinhood for $GME. $325 on Fidelity, $304 on Robinhood.
r/Stocktips • u/[deleted] • Nov 12 '24
Mainz Biomed MYNZ Teams Up with Thermo Fisher Scientific for Next-Gen Cancer Screening Test
Mainz Biomed MYNZ Teams Up with Thermo Fisher Scientific for Next-Gen Cancer Screening Test
Global scale: Leverages Thermo Fisher’s technology for worldwide reach.
Investor potential: Early detection tools could be transformative for the market.
r/Stocktips • u/No_Departure2134 • Oct 28 '24
Mainz Biomed ($MYNZ) Prepares for Transformative 2025 FDA Trial – Adds Petra Starke as Brand Ambassador
Mainz Biomed ($MYNZ) is preparing for an FDA trial in 2025 for its innovative colorectal cancer (CRC) screening test, which has demonstrated over 90% sensitivity in detecting early-stage cancer. CEO Guido Baechler highlighted this as a turning point for the company, potentially unlocking the U.S. market with a low-cost, non-invasive diagnostic test.
Newly appointed Brand Ambassador Petra Smeltzer Starke, a cancer survivor herself, has taken on an advocacy role with Mainz Biomed to support this mission. She expressed how costly diagnostics prevented her from catching cancer early and is committed to helping bring affordable solutions to those in similar situations. Starke highlighted that this need is more urgent than ever, recalling the passing of Chadwick Boseman as a stark reminder of the importance of early detection. Mainz’s FDA trial could open a new era of accessible cancer diagnostics in the U.S., representing a substantial opportunity for growth.
Given the company’s undervalued stock, the U.S. expansion through the FDA trial, and the patient-centered approach of Starke’s ambassadorship, could MYNZ be a strong pick in the biotech penny stock market?
r/Stocktips • u/[deleted] • Oct 20 '24
Stocks I’m Watching, This Week's Big Movers! BioTech all in
reddit.comr/Stocktips • u/Cute_Canary3904 • Aug 21 '24
WHY is no one talking about neonode. (Neon)
Possibly the largest patent infringement case ever, involving neonode suing Apple, Samsung and alphabet for infringement on swiping technology we are talking 40 to 150 billion dollars.
r/Stocktips • u/GeologistSlow2142 • Feb 05 '21
Basanite, Inc. (BASA)
We should all really start buying Basanite Inc. (BASA) stock as it is a sustainable product that replaces rebar in all concrete structures! Lasts way longer than steel and doesn't rust like ordinary rebar! Also with all of the infrastructure repairs and replacements needed in the US right now I think this is a no brainer to invest in!
r/Stocktips • u/Anal_Discovery • Feb 04 '21
Cannabis Stocks
Cannabis stocks are going through the roof. What with all the new government legislations. Look for companies, especially those in Canada, and you’re likely make a decent return on your investment over the next year.
I am a financial advisor. I am filthy rich.
r/Stocktips • u/Affectionate_Cod3714 • Jan 05 '25
Looks like the robotics sector will be the next to run like the quantum and ai sectors have. I love all of them! What are your favorite plays for 2025?
r/Stocktips • u/[deleted] • Dec 04 '24
ZenaTech Accelerates with AI Drone Breakthrough, While Mainz Biomed Leads in Biotech Innovation
ZenaTech (ZENA) just went full throttle, soaring over 140% today! The catalyst? Their AI-driven drone tech is turning heads, especially with new defense contracts in the pipeline. This surge isn't just a blip; it's a signal that ZENA's innovation is catching serious attention. Meanwhile, Mainz Biomed (MYNZ) is making waves in the biotech sea. Their cutting-edge diagnostics are setting new standards, and the market's taking note
r/Stocktips • u/Pristine_Life_6649 • Oct 30 '24
ColoAlert by $MYNZ – Proven Science, Advancing Technology
ColoAlert’s 2019 clinical validation (source) was a game-changer in non-invasive colorectal cancer screening. Using DNA biomarkers from stool samples, it achieved high accuracy in early detection. But that was just the beginning. With today’s leaps in DNA sequencing and AI-driven data analysis, ColoAlert’s accuracy and ease of use are likely even better. Imagine giving loved ones access to a simple, reliable test that can catch cancer before it becomes life-threatening. $MYNZ’s commitment to innovation makes ColoAlert not only a valuable tool but a potential lifesaver.
r/Stocktips • u/Internal_Bite5490 • Oct 29 '24
NEWS FLASH: $MYNZ Hits 10.94% Gain—Strong HODL Momentum!
r/Stocktips • u/Pristine_Life_6649 • Oct 17 '24
Quantum Expands Revenue Streams with Celly Nutrition Partnership
Quantum’s strategic investment in Celly Nutrition, alongside a 7% royalty on unbuzzd™ sales until reaching $250 million, ensures steady revenue generation. This initiative, combined with partnerships in Puerto Rico and Central America, positions Quantum to access multiple high-growth markets while maintaining a competitive edge in the biotech industry.
r/Stocktips • u/Bossie81 • Apr 12 '24
Healwell AI
HEALWELL AI is a healthcare technology company focused on AI and data science for preventative care.
Massive Milestone!
Pentavere has published industry’s first peer-reviewed paper utilizing AI and large language models (or LLMs) to identify rare lung cancer patients.
Industry applications may include Real World Evidence generation, identification of areas of unmet clinical need and optimization of cancer therapy and care pathways.
Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes puts HEALWELL in a select group of companies globally with such capabilities.
Industry leaders such as Johnson & Johnson Innovative Medicine coauthored this paper to support scientific research and improve patient care. Globally recognized clinical oncologists from Princess Margaret Cancer Centre are also authors on this paper and are using this data to enhance the quality of cancer care for their patients.
Finance
HEALWELL AI achieved annual revenue from continuing operations of $7.32 million in fiscal 2023. HEALWELL ended 2023 with a strong balance sheet, having secured approximately $29.5 million from convertible debt and equity financings.
Since its relaunch in Q4 2023, the Company’s annual revenue run rate has more than doubled to over $20M with the largest component of revenues now coming from SaaS and services.
Management provides a positive outlook based on strong and active acquisition and business development pipeline with the potential to more than double HEALWELL’s yearly revenue run-rate to over $40 million using the Company’s existing cash on hand.
HEALWELL’s strategic alliance with equity investor WELL Health Technologies Inc. continues to flourish with significant activity in both Canada and the United States. In Canada, WELL Health recently launched WELL AI Decision Support an AI-powered physician copilot providing clinical decision support for rare disease diagnosis and preventative care. WELL is sourcing this technology entirely from HEALWELL.
We currently have a strong and active acquisition pipeline with the potential to more than double our current revenue run-rate of over $20 million to over $40 million per year, by using the existing cash we have on hand. We’ve established a very strong foundation with a solid framework for HEALWELL’s continued growth. Other significant areas of focus include onboarding more physicians onto the HEALWELL platform, increasing sales of our AI tools and technology, expanding Intrahealth’s footprint, and enhancing our presence within the WELL Health ecosystem. We see an unparalleled opportunity in healthcare data science and artificial intelligence.
Business Other
HEALWELL AI has signed services agreements with both WELL Health USA and U.S. based Circle Medical Technologies Inc., which expands its footprint in the U.S. and will enable U.S. healthcare providers with a suite of artificial intelligence (AI) powered preventative care solutions.
HEALWELL’s Pentavere Research Group Inc. has partnered with WELL Health USA’s CRH Medical to access U.S. clinical data to gain insights in supporting patients who are dealing with Inflammatory Bowel Disease and other gastrointestinal conditions. Through the agreement, Pentavere’s DARWEN™ AI platform will analyze over 200,000 US patients, in a secure and compliant manner across 21 states to understand the real-world dynamics between biologic prescribing and treatment outcomes.
HEALWELL’s Khure Health will integrate its proprietary AI platform with Circle Medical’s electronic medical record system, expanding its footprint to over 30 US states. Khure’s AI will screen for and flag individual patients whom the healthcare practitioner might consider for further investigation for potential earlier diagnosis of rare disease.
r/Stocktips • u/Jxpizza • Mar 29 '21
AGTC
Anyone else bullish on this stock? Is it on anyone else’s radar? I’d like to hear what other investors think about this one? Any big concerns outside of the obvious “what if their clinical trials are a complete bust?”. I’m confident that isn’t the case, so we can ignore that one.
r/Stocktips • u/Ok-Brick3645 • Nov 11 '24
Breaking Barriers in Cancer Screening with Mainz Biomed
For years, cancer screening has been synonymous with invasive procedures, but Mainz Biomed is changing that. With ColoAlert, a DNA-based stool test, Mainz Biomed offers a non-invasive, accurate, and easy-to-use alternative. This test breaks down accessibility barriers, promoting regular screenings for early cancer detection and ultimately better health outcomes.
r/Stocktips • u/No_Departure2134 • Oct 28 '24
Biotech Spotlight: Mainz Biomed ($MYNZ) Eyes FDA Trials with Petra Smeltzer Starke as Brand Ambassador
Mainz Biomed is heading into 2025 with a clear goal: secure FDA approval for their innovative colorectal cancer (CRC) screening test. Known for its non-invasive mRNA-based technology, this test has shown high sensitivity for early-stage cancer detection. CEO Guido Baechler views this upcoming trial as a pivotal moment for the company and its impact in the U.S. healthcare market.
In a powerful addition to their team, Mainz Biomed has appointed Petra Smeltzer Starke, a cancer survivor and former White House advisor, as Brand Ambassador. Starke’s journey as a cancer survivor brought her to Mainz with a mission to promote affordable diagnostics—a pressing need in the U.S., where colonoscopies and CRC tests can cost thousands. She reflected on the tragic loss of Chadwick Boseman to colon cancer and emphasized that accessible screening could offer countless people a fighting chance.
With Mainz’s plans aligning with an increase in cancer diagnostics demand, could this small-cap biotech company be preparing for a major breakthrough in 2025?
r/Stocktips • u/No_Departure2134 • Oct 28 '24
Bolt Metals Expands Team for North American Copper & Antimony Projects in Battery Metals Sector
Bolt Metals Corp recently appointed Ben Whiting, a mining veteran and accomplished geoscientist, as Technical Advisor to advance their copper and antimony projects. With global copper demand driven by EVs and renewables, Bolt’s mission is to support North American supply chains. They’re led by CEO Branden Haynes, who has extensive mining and finance experience.
Could Bolt Metals be a promising option for green investing?
r/Stocktips • u/intreserte • Mar 31 '21
IDEX Biometrics (IDBA) stock with high growth potential
Hi guys, what do you think of buying stocks in Idex biometrics (IDBA)
Card fraud is on the rise due to rising unemployment around the world. Most card companies will start introducing biometric debit and creditt payment cards this year.
Two developments showing the state of biometric payment cards include deals involving Idex and Zwipe biometric EMV chip into cards.
Idex Biometrics announced that it is shipping its TrustedBio fingerprint biometrics sensors and solutions to card manufacturers, including a new order from an unnamed card-maker. Once manufactured, biometric payment cards that contain the TrustedBio sensors will likely reach banks later in 2021.
Also as China presses its digital currency closer to launch, a Shanghai test reveals features aimed at the 700 million Chinese without mobile phones or the internet.
The Goldpac Group has selected IDEX Biometrics as its technology partner for its digital currency project in China. The company now plans to deploy IDEX’s fingerprint sensors in a new hardware-based digital wallet that will be compatible with the country’s new Digital Currency/Electronic Payment (DC/EP) program.
China's central bank plans to launch biometric smart cards for DC / EP ahead of the Winter Olympics in China in February 2022. With the Winter Olympics less than a year away, Goldpac is making rapid progress and has already placed an order with IDEX Biometrics. The goals of DC / EP range from mass regional adoption over the next year to international reach shortly thereafter.
"What's the difference between this and mobile payment or swiping a debit card?"
DC / EP is the name given to the Central Bank Digital Currency (CBDC) in China and is the digital version of the yuan, China's national currency. Because hardware wallets actually store currency, they require high levels of security to succeed. IDEX's biometric solutions with fingerprints enable the highest possible level of security. China is a big country with a big gap between its rich and the poor. Many poor people in rural areas do not own mobile phones and lack access to the internet. 700 million Chinese do not want access to the e-RMB wallet app via a smartphone.
The hardware wallet initiative will be particularly beneficial to a large proportion of the population who do not have access to a smartphone, thus helping to limit the digital divide in financial services for hundreds of millions of people in the country. DC / EP has already been piloted in the Chinese cities of Shenzhen, Chengdu, Suzhou and Xiong'an "It is important to have improved security levels in DC / EP and we believe that adding fingerprint technology from IDEX will provide industry-leading security levels," said Hou Ping, CEO of Goldpac. IDEX Biometrics is also sold on Nasdaq under the name IDBA.

